283 related articles for article (PubMed ID: 7743475)
21. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
22. Assessment of cellular proliferation of eccrine acrospiromas and eccrine sweat gland carcinomas by AgNOR counting and immunohistochemical demonstration of proliferating cell nuclear antigen (PCNA) and Ki-67.
Ansai S; Koseki S; Hozumi Y; Kondo S
Clin Exp Dermatol; 1995 Jan; 20(1):27-34. PubMed ID: 7671392
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the proliferation state in canine mammary tumors by the standardized AgNOR method with postfixation and immunohistologic detection of Ki-67 and PCNA.
Löhr CV; Teifke JP; Failing K; Weiss E
Vet Pathol; 1997 May; 34(3):212-21. PubMed ID: 9163877
[TBL] [Abstract][Full Text] [Related]
24. Sarcomatoid renal cell carcinoma. A study of its proliferative activity.
Oda H; Machinami R
Cancer; 1993 Apr; 71(7):2292-8. PubMed ID: 8095849
[TBL] [Abstract][Full Text] [Related]
25. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Lehmann J; Retz M; Nürnberg N; Schnöckel U; Raffenberg U; Krams M; Kellner U; Siemer S; Weichert-Jacobsen K; Stöckle M
Cancer; 2004 Oct; 101(7):1552-62. PubMed ID: 15378494
[TBL] [Abstract][Full Text] [Related]
26. Improving accuracy in the grading of renal cell carcinoma by combining the quantitative description of chromatin pattern with the quantitative determination of cell kinetic parameters.
François C; Moreno C; Teitelbaum J; Bigras G; Salmon I; Danguy A; Brugal G; van Velthoven R; Kiss R; Decaestecker C
Cytometry; 2000 Feb; 42(1):18-26. PubMed ID: 10679739
[TBL] [Abstract][Full Text] [Related]
27. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analyses.
Ghazizadeh M; Sasaki Y; Araki T; Konishi H; Aihara K
Am J Clin Pathol; 1997 Apr; 107(4):451-8. PubMed ID: 9124214
[TBL] [Abstract][Full Text] [Related]
29. Cell kinetic study of thymic epithelial tumors using PCNA (PC10) and Ki-67 (MIB-1) antibodies.
Yang WI; Efird JT; Quintanilla-Martinez L; Choi N; Harris NL
Hum Pathol; 1996 Jan; 27(1):70-6. PubMed ID: 8543314
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of p53, PCNA, Ki-67, MDM2 and AgNOR in oral peripheral and central giant cell lesions.
Souza PE; Mesquita RA; Gomez RS
Oral Dis; 2000 Jan; 6(1):35-9. PubMed ID: 10673786
[TBL] [Abstract][Full Text] [Related]
31. MCM - 2 and Ki - 67 as proliferation markers in renal cell carcinoma: A quantitative and semi - quantitative analysis.
Mehdi MZ; Nagi AH; Naseem N
Int Braz J Urol; 2016; 42(6):1121-1128. PubMed ID: 27532114
[TBL] [Abstract][Full Text] [Related]
32. The prognostic importance of the nucleolar organizer region (AgNOR), Ki-67 and proliferating cell nuclear antigen (PCNA) in primary nonurachal bladder adenocarcinoma.
Ozdemir BH; Ozdemir OG; Sertçelik A
APMIS; 2001 Jun; 109(6):428-34. PubMed ID: 11506474
[TBL] [Abstract][Full Text] [Related]
33. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
Yu CC; Dublin EA; Camplejohn RS; Levison DA
Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
[TBL] [Abstract][Full Text] [Related]
34. Incidence of apoptosis, cell proliferation and P53 expression in renal cell carcinomas.
Tannapfel A; Hahn HA; Katalinic A; Fietkau RJ; Kühn R; Wittekind CW
Anticancer Res; 1997; 17(2A):1155-62. PubMed ID: 9137464
[TBL] [Abstract][Full Text] [Related]
35. Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma.
Zhang X; Takenaka I
Urology; 2000 Sep; 56(3):510-5. PubMed ID: 10962335
[TBL] [Abstract][Full Text] [Related]
36. A multilabeling technique for simultaneous demonstration and quantitation of Ki-67 and nucleolar organizer regions (AgNORs) in paraffin-embedded tissue.
Munakata S; Hendricks JB
J Histochem Cytochem; 1994 Jun; 42(6):789-3. PubMed ID: 7514625
[TBL] [Abstract][Full Text] [Related]
37. Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract.
Lee CS
Cancer; 1996 Nov; 78(9):1881-7. PubMed ID: 8909306
[TBL] [Abstract][Full Text] [Related]
38. Proliferative activity is a significant prognostic factor in male breast carcinoma.
Pich A; Margaria E; Chiusa L
Am J Pathol; 1994 Aug; 145(2):481-9. PubMed ID: 7519830
[TBL] [Abstract][Full Text] [Related]
39. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.
Cher ML; Chew K; Rosenau W; Carroll PR
Prostate; 1995 Feb; 26(2):87-93. PubMed ID: 7855002
[TBL] [Abstract][Full Text] [Related]
40. Comparative assessment of proliferating cell nuclear antigen immunostaining and of nucleolar organizer region staining in transitional cell carcinomas of the urinary bladder. Correlation with other conventional prognostic pathologic parameters.
Skopelitou A; Korkolopoulou P; Papanicolaou A; Christodoulou P; Thomas-Tsagli E; Pavlakis K
Eur Urol; 1992; 22(3):235-40. PubMed ID: 1361436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
